A Phase 1b, Open-label Trial to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of NDI-5001 in a Capsule Following Daily Oral Doses to Adult Males With X-linked Congenital Nephrogenic Diabetes Insipidus
Latest Information Update: 21 Apr 2026
At a glance
- Drugs NDI 5001 (Primary)
- Indications Diabetes insipidus
- Focus Therapeutic Use
- Sponsors Otsuka Pharmaceutical Development & Commercialization
Most Recent Events
- 21 Apr 2026 New trial record